These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30821532)

  • 21. When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing.
    Balderrama F; Schwartz LJ; Longo CJ
    Health Care Anal; 2020 Jun; 28(2):121-136. PubMed ID: 32232611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk sharing in managed entry agreements-A review of the Swedish experience.
    Andersson E; Svensson J; Persson U; Lindgren P
    Health Policy; 2020 Apr; 124(4):404-410. PubMed ID: 32093981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Italian risk-sharing agreements on drugs: are they worthwhile?
    Garattini L; Curto A; van de Vooren K
    Eur J Health Econ; 2015 Jan; 16(1):1-3. PubMed ID: 24728513
    [No Abstract]   [Full Text] [Related]  

  • 25. [Innovative patient access schemes for the adoption of new technology: risk-sharing agreements].
    Espín J; Oliva J; Rodríguez-Barrios JM
    Gac Sanit; 2010; 24(6):491-7. PubMed ID: 21074292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach.
    Al-Omar HA; Alghannam HH; Aljuffali IA
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):837-845. PubMed ID: 32658625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Risk sharing agreements: with orphan drugs?].
    Campillo-Artero C; del Llano J; Poveda JL
    Farm Hosp; 2012; 36(6):455-63. PubMed ID: 23461437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 31. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
    Adamski J; Godman B; Ofierska-Sujkowska G; Osińska B; Herholz H; Wendykowska K; Laius O; Jan S; Sermet C; Zara C; Kalaba M; Gustafsson R; Garuolienè K; Haycox A; Garattini S; Gustafsson LL
    BMC Health Serv Res; 2010 Jun; 10():153. PubMed ID: 20529296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The hidden cost of low prices: limited access to new drugs in India.
    Berndt ER; Cockburn IM
    Health Aff (Millwood); 2014 Sep; 33(9):1567-75. PubMed ID: 25201661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.
    Moreno-Torres I; Puig-Junoy J; Raya JM
    Eur J Health Econ; 2011 Dec; 12(6):563-73. PubMed ID: 20809092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Establishing the value of new drugs in Italy.].
    Villa F; Jommi C; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G
    Recenti Prog Med; 2020 Feb; 111(2):65-69. PubMed ID: 32089554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?
    McGuire A; Drummond M; Martin M; Justo N
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):599-605. PubMed ID: 26176751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical risk-sharing agreements.
    Cook JP; Vernon JA; Manning R
    Pharmacoeconomics; 2008; 26(7):551-6. PubMed ID: 18563946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
    Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
    Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia (Spain).
    Guarga L; Gasol M; Reyes A; Roig M; Alonso E; Clopés A; Delgadillo J
    Value Health; 2022 May; 25(5):803-809. PubMed ID: 35500950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.